Συγγραφείς:
Dimopoulos, M.A.
Moreau, P.
Terpos, E.
Mateos, M.V.
Zweegman, S.
Cook, G.
Delforge, M.
Hájek, R.
Schjesvold, F.
Cavo, M.
Goldschmidt, H.
Facon, T.
Einsele, H.
Boccadoro, M.
San-Miguel, J.
Sonneveld, P.
Mey, U.
EHA Guidelines Committee
ESMO Guidelines Committee
Λέξεις-κλειδιά:
antineoplastic agent; bortezomib; busulfan; carfilzomib; cyclophosphamide; dexamethasone; doxorubicin; lenalidomide; melphalan; prednisone; thalidomide, Article; autologous stem cell transplantation; cancer diagnosis; cancer incidence; cancer radiotherapy; cancer staging; cancer survival; cancer therapy; consolidation chemotherapy; differential diagnosis; epidemiological data; follow up; graft versus host reaction; human; long term care; maintenance therapy; multiple myeloma; personalized medicine; plasma cell leukemia; plasmacytoma; practice guideline; relapse; risk benefit analysis; treatment response; follow up; medical society; multiple myeloma; practice guideline, Follow-Up Studies; Humans; Multiple Myeloma; Societies, Medical
